Benjamin Resio, MD
Assistant ProfessorAbout
Research
Publications
2026
Use of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original ResearchConceptsCohort studyManagement of breast cancerBreast cancerCohort study of dataMedical management of breast cancerTreated with CAMCox proportional hazards modelsMedical managementYear of diagnosisFemale patientsCombination of CAMProportional hazards modelTraditional therapiesAlternative medicineStudy of dataMain OutcomesEndocrine therapyNo treatmentCharlson Comorbidity IndexInsurance typeNonmedical personnelPrimary outcomeFacility typeSurvival timeHazards model
2025
P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2025, 20: s148-s149. DOI: 10.1016/j.jtho.2025.09.274.Peer-Reviewed Original ResearchP2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy. Journal Of Thoracic Oncology 2025, 20: s343. DOI: 10.1016/j.jtho.2025.09.643.Peer-Reviewed Original ResearchReal-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer. JTCVS Open 2025, 28: 554-564. PMID: 41473080, PMCID: PMC12745116, DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsMortality Risk and Cause of Death Associated With Removal of the Adult Thymus: Analysis of the U.S. Thymoma Population
Resio B, Canavan M, Caturegli G, Detterbeck F, Boffa D. Mortality Risk and Cause of Death Associated With Removal of the Adult Thymus: Analysis of the U.S. Thymoma Population. Journal Of Thoracic Oncology 2025, 21: 186-194. PMID: 40865907, DOI: 10.1016/j.jtho.2025.08.017.Peer-Reviewed Original ResearchSurveillance Epidemiology and End ResultsNational Cancer DatabaseDuctal carcinoma in situPropensity-matched patientsThyroid cancerAdult thymusU.S. populationImmunologic end pointsCarcinoma in situFive-year survivalCancer incidencePartial thymectomyThyroid lobectomyResected breastLonger-term outcomesPartial mastectomyThyroid neoplasmsTotal thymectomyCancer DatabaseCause of deathNo significant differenceSecondary cancersSmall thymomaThymectomyEnd ResultsProlonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis
Zhan P, Canavan M, Bader J, Boffa D, Resio B, Woodard G. Prolonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis. The Annals Of Thoracic Surgery 2025, 121: 633-642. PMID: 40588180, DOI: 10.1016/j.athoracsur.2025.06.015.Peer-Reviewed Original ResearchNational Cancer DatabaseLong-term survivalSurgical resectionOverall survivalPleural mesotheliomaClinical stage I diseaseCurative-intent surgical resectionNational Cancer Database dataNational Cancer Database AnalysisDiagnosis of malignant pleural mesotheliomaDeclined surgical resectionEpithelioid histological typeChemotherapy-treated patientsNonsurgically treated patientsStage I diseaseMalignant pleural mesotheliomaMultivariate logistic regression modelPropensity-matched cohortPropensity score matchingI diseaseSurvival benefitHistological typeSurgery 2Prolonged survivalCancer DatabaseDefinitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodSurvival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
Ayoade O, Canavan M, Caturegli G, Zolfaghari E, Resio B, Woodard G, Boffa D. Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status. Journal Of Clinical Oncology 2025, 43: e24041-e24041. DOI: 10.1200/jco.2025.43.16_suppl.e24041.Peer-Reviewed Original ResearchCancer patient survivalPatient survivalTumor behaviorCOVID-19 infectionCancer typesCharlson-Deyo scoreNational Cancer DatabaseSurvival of patientsKaplan Meier analysisCox proportional hazards modelsStage IV cancerAssociated with lower mortality riskProportional hazards modelCOVID-positive patientsMeier analysisCancer DatabaseLower mortality riskPositive patientsTreatment modalitiesDeyo scoreIV cancerImmune modulationImmunological consequencesCancer patientsYear mortalitySmoking Status of the US Cancer Population and a New Perspective From the National Cancer Database
Caturegli G, Zhu X, Palis B, Mullett T, Resio B, Boffa D. Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database. JAMA Oncology 2025, 11: 564-566. PMID: 40146125, PMCID: PMC11950973, DOI: 10.1001/jamaoncol.2025.0247.Peer-Reviewed Original Research
2024
Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection
Resio B, Tan K, Skovgard M, Dycoco J, Adusumilli P, Bains M, Bott M, Downey R, Gray K, Huang J, Molena D, Park B, Rusch V, Sihag S, Rocco G, Jones D, Isbell J. Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection. The Annals Of Thoracic Surgery 2024, 119: 308-315. PMID: 39299477, PMCID: PMC12453556, DOI: 10.1016/j.athoracsur.2024.09.009.Peer-Reviewed Original ResearchConceptsClinical stage IClinical stage III patientsStage III patientsStage IIII patientsLung resectionHilar lymph node stationsRate of nodal upstagingSystemic therapy administrationProspective institutional databaseLung cancer resectionLymph node stationsIn-Hospital ComplicationsLymph node samplingLung cancer patientsDistant recurrenceNodal upstagingOncological outcomesPulmonary resectionOverall survivalCancer resectionDecrease recurrenceClinical stageII patientsImproved survival
Academic Achievements & Community Involvement
Clinical Care
Overview
Benjamin Resio, MD, is a thoracic surgeon who treats the entire spectrum of thoracic surgical diseases. He has a special interest in thoracic surgical oncology, multidisciplinary care for lung and esophageal cancer, and minimally invasive and robotic surgery. Dr. Resio cares for patients as part of the Center for Thoracic Cancers at Smilow Cancer Hospital.
Also an assistant professor of surgery at Yale School of Medicine, Dr. Resio received his medical degree with honors from Dartmouth Medical School, where he was elected to the Alpha Omega Alpha honor society. He completed his residency at Yale School of Medicine, followed by a fellowship in cardiothoracic surgery at Memorial Sloan Kettering Cancer Center.
Clinical Specialties
Thoracic Surgery
Yale Medicine News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.